Exposure to phenytoin associates with a lower risk of post-COVID cognitive deficits: a cohort study.

Patients with a therapeutic phenytoin level ( n = 240) were at a lower risk of post-COVID cognitive impairment than those with a subtherapeutic phenytoin level ( n = 219; the total number is less than the number of individuals on phenytoin because several patients on phenytoin did not have a level recorded during the pandemic), but this did not reach statistical significance (HR 0.76, 95% CI 0.55–1.05, P = 0.091), except when focusing on the later phase of follow up (weighted log-rank P = 0.021).

also in 111,027 other papers